JP Morgan Maintains Overweight on TransMedics Gr, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Thomas Allen maintains an Overweight rating on TransMedics Gr (NASDAQ:TMDX) and raises the price target from $67 to $70.
November 07, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on TransMedics Gr and raises the price target from $67 to $70, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for TransMedics Gr. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100